Hu Zhi-Xing, Yang Chao, Fang Luo-Chang-Ting, Wang Xiao-Xiao, Li Qun, Chen Wei-Heng, Zhang Yan-Qiong, Lin Ya, Liu Chun-Fang, Lin Na
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
Third Affiliated Hospital, Beijing University of Chinese Medicine Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi. 2023 Nov;48(22):6128-6141. doi: 10.19540/j.cnki.cjcmm.20230815.701.
The approach combining disease, syndrome, and symptom was employed to investigate the characteristic changes of blood stasis syndrome in a rat model of steroid-induced osteonecrosis of the femoral head(SONFH) during disease onset and progression. Seventy-two male SD rats were randomized into a healthy control group and a model group. The rat model of SONFH was established by injection of lipopolysaccharide(LPS) in the tail vein at a dose of 20 μg·kg(-1)·d(-1) on days 1 and 2 and gluteal intramuscular injection of methylprednisolone sodium succinate(MPS) at a dose of 40 mg·kg(-1)·d(-1) on days 3-5, while the healthy control group received an equal volume of saline. The mechanical pain test, tongue color RGB technique, gait detection, open field test, and inclined plane test were employed to assess hip pain, tongue color, limping, joint activity, and lower limb strength, respectively, at different time points within 21 weeks of modeling. At weeks 2, 4, 8, 12, 16, and 21 after modeling, histopathological changes of the femoral head were observed by hematoxylin-eosin(HE) staining and micro-CT scanning; four coagulation items were measured by rotational thromboelastometry; and enzyme-linked immunosorbent assay(ELISA) was employed to determine the levels of six blood lipids, vascular endothelial growth factor(VEGF), endothelin-1(ET-1), nitric oxide(NO), tissue-type plasminogen activator(t-PA), plasminogen activator inhibitor factor-1(PAI-1), bone gla protein(BGP), alkaline phosphatase(ALP), receptor activator of nuclear factor-κB(RANKL), osteoprotegerin(OPG), and tartrate-resistant acid phosphatase 5b(TRAP5b) in the serum, as well as the levels of 6-keto-prostaglandin 1α(6-keto-PGF1α) and thromboxane B2(TXB2) in the plasma. The results demonstrated that the pathological alterations in the SONFH rats were severer over time. The bone trabecular area ratio, adipocyte number, empty lacuna rate, bone mineral density(BMD), bone volume/tissue volume(BV/TV), trabecular thickness(Tb.Th), trabecular number(Tb.N), bone surface area/bone volume(BS/BV), and trabecular separation(Tb.Sp) all significantly increased or decreased over the modeling time after week 4. Compared with the healthy control group, the mechanical pain threshold, gait swing speed, stride, standing time, and walking cycle of SONFH rats changed significantly within 21 weeks after modeling, with the greatest difference observed 12 weeks after modeling. The time spent in the central zone, rearing score, and maximum tilt angle in the open field test of SONFH rats also changed significantly over the modeling time. Compared with the healthy control group, the R, G, and B values of the tongue color of the model rats decreased significantly, with the greatest difference observed 11 weeks after modeling. The levels of total cholesterol(TC), total triglycerides(TG), low-density lipoprotein-cholesterol(LDL-C), and apoprotein B(ApoB) in the SONFH rats changed significantly 4 and 8 weeks after modeling. The levels of VEGF, ET-1, NO, t-PA, PAI-1, 6-keto-PGF1α, TXB2, four coagulation items, and TXB2/6-keto-PGF1α ratio in the serum of SONFH rats changed significantly 4-16 weeks after modeling, with the greatest differences observed 12 weeks after modeling. The levels of BGP, TRAP5b, RANKL, OPG, and RANKL/OPG ratio in the serum of SONFH rats changed significantly 8-21 weeks after modeling. During the entire onset and progression of SONFH in rats, the blood stasis syndrome characteristics such as hyperalgesia, tongue color darkening, gait abnormalities, platelet, vascular, and coagulation dysfunctions were observed, which gradually worsened and then gradually alleviated in the disease course(2-21 weeks), with the most notable differences occurred around 12 weeks after modeling.
采用疾病、证型和症状相结合的方法,研究激素性股骨头坏死(SONFH)大鼠模型在疾病发生和发展过程中血瘀证的特征性变化。72只雄性SD大鼠随机分为健康对照组和模型组。通过在第1天和第2天尾静脉注射剂量为20 μg·kg⁻¹·d⁻¹的脂多糖(LPS),并在第3 - 5天臀肌注射剂量为40 mg·kg⁻¹·d⁻¹的甲泼尼龙琥珀酸钠(MPS)建立SONFH大鼠模型,而健康对照组注射等量生理盐水。在建模的21周内,分别在不同时间点采用机械疼痛试验、舌色RGB技术、步态检测、旷场试验和斜面试验评估髋部疼痛、舌色、跛行、关节活动和下肢力量。在建模后第2、4、8、12、16和21周,通过苏木精 - 伊红(HE)染色和显微CT扫描观察股骨头的组织病理学变化;采用旋转血栓弹力图法检测四项凝血指标;采用酶联免疫吸附测定(ELISA)法测定血清中六种血脂、血管内皮生长因子(VEGF)、内皮素 - 1(ET - 1)、一氧化氮(NO)、组织型纤溶酶原激活剂(t - PA)、纤溶酶原激活剂抑制因子 - 1(PAI - 1)、骨钙蛋白(BGP)、碱性磷酸酶(ALP)、核因子κB受体激活剂(RANKL)、骨保护素(OPG)和抗酒石酸酸性磷酸酶5b(TRAP5b)的水平,以及血浆中6 - 酮 - 前列腺素1α(6 - 酮 - PGF1α)和血栓素B2(TXB2)的水平。结果表明,SONFH大鼠的病理改变随时间加重。在第4周后的建模时间内,骨小梁面积比、脂肪细胞数量、空骨陷窝率、骨密度(BMD)、骨体积/组织体积(BV/TV)、骨小梁厚度(Tb.Th)、骨小梁数量(Tb.N)、骨表面积/骨体积(BS/BV)和骨小梁间距(Tb.Sp)均显著增加或减少。与健康对照组相比,SONFH大鼠的机械疼痛阈值、步态摆动速度、步幅、站立时间和行走周期在建模后21周内发生显著变化,在建模后12周差异最大。SONFH大鼠在旷场试验中的中央区域停留时间、直立评分和最大倾斜角度在建模时间内也发生显著变化。与健康对照组相比,模型大鼠舌色的R、G和B值显著降低,在建模后11周差异最大。SONFH大鼠血清中总胆固醇(TC)、总甘油三酯(TG)、低密度脂蛋白胆固醇(LDL - C)和载脂蛋白B(ApoB)的水平在建模后4周和8周发生显著变化。SONFH大鼠血清中VEGF、ET - 1、NO、t - PA、PAI - 1、6 - 酮 - PGF1α、TXB2、四项凝血指标以及TXB2/6 - 酮 - PGF1α比值在建模后4 - 16周发生显著变化,在建模后12周差异最大。SONFH大鼠血清中BGP、TRAP5b、RANKL、OPG和RANKL/OPG比值在建模后8 - 21周发生显著变化。在大鼠SONFH发病和发展的整个过程中,观察到血瘀证特征,如痛觉过敏、舌色变暗、步态异常、血小板、血管和凝血功能障碍,这些特征在病程(2 - 21周)中逐渐加重然后逐渐缓解,在建模后约12周差异最为显著。